APHINITY | Journal of Clinical Oncology

APHINITY | Journal of Clinical Oncology

OVERVIEW The human epidermal growth factor receptor 2 (HER2) is the second most important target for systemic breast cancer (BC) therapy after the estrogen receptor. HER2 overexpression is found in 15%-20% of patients with BC. Today, HER2-directed therapies are...
Cardiac Safety in the APHINITY trial

Cardiac Safety in the APHINITY trial

OVERVIEW ESMO Open has published an article co-authored by a member of our Biostatistics team. Results of the exploratory analysis conclude that after >6 years of median follow-up, pertuzumab and trastuzumab did not increase cardiotoxicity risk compared to...
APHINITY | Annals of Oncology

APHINITY | Annals of Oncology

Title of Publication Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up AUTHORS Loibl, S; Jassem, J; Sonnenblick, A; Parlier, D; Winer, E; Bergh, J; Gelber, RD; Restuccia, E; Im, YH; Huang,...
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

TITLE OF PUBLICATION Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial Authors Richard D.Gelber; Xin V.Wang; Bernard F.Cole; David...